Cellebrite Enhances Guardian with Faster, First-to-Market Evidence Review Capabilities
Go back to Cellebrite Enhances Guardian with Faster, First-to-Market Evidence Review Capabilities| (NASDAQ: CLBT) | Delayed: 10.18 -5.07 (33.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.25 | 52 Week High | $ | |||
| Open | $10.32 | 52 Week Low | $ | |||
| Day High | $10.62 | P/E | N/A | |||
| Day Low | $9.58 | EPS | $ | |||
| Volume | 17,817,357 | |||||
| (NASDAQ: CLBTW) | Delayed: 5.25 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.25 | 52 Week High | $ | |||
| Open | $5.25 | 52 Week Low | $ | |||
| Day High | $5.25 | P/E | N/A | |||
| Day Low | $5.25 | EPS | $ | |||
| Volume | 2,538 | |||||
